Tiziana Life Sciences Announces Purchase of Shares by Chairman
Tiziana Life Sciences (NASDAQ: TLSA) announced that Executive Chairman and Founder Gabriele Cerrone has increased his stake in the company through the purchase of 15,000 common shares at $1.55 per share. Following this transaction, Cerrone's total holdings have reached 43,252,143 common shares, representing 37.02% of the company's issued share capital. Tiziana is developing immunomodulation therapies, with its lead candidate being intranasal foralumab, a fully human anti-CD3 monoclonal antibody.
Tiziana Life Sciences (NASDAQ: TLSA) ha annunciato che il Presidente Esecutivo e Fondatore Gabriele Cerrone ha aumentato la sua partecipazione nella società acquistando 15.000 azioni ordinarie al prezzo di 1,55$ per azione. Dopo questa operazione, la quota totale detenuta da Cerrone è salita a 43.252.143 azioni ordinarie, corrispondenti al 37,02% del capitale sociale emesso. Tiziana sta sviluppando terapie di immunomodulazione, con il suo principale candidato terapeutico rappresentato dal foralumab intranasale, un anticorpo monoclonale anti-CD3 completamente umano.
Tiziana Life Sciences (NASDAQ: TLSA) anunció que el Presidente Ejecutivo y Fundador Gabriele Cerrone ha incrementado su participación en la compañía mediante la compra de 15,000 acciones ordinarias a $1.55 por acción. Tras esta transacción, la participación total de Cerrone alcanzó 43,252,143 acciones ordinarias, lo que representa el 37.02% del capital social emitido por la empresa. Tiziana está desarrollando terapias de inmunomodulación, siendo su candidato principal el foralumab intranasal, un anticuerpo monoclonal anti-CD3 totalmente humano.
Tiziana Life Sciences (NASDAQ: TLSA)는 최고경영자 겸 창립자인 가브리엘레 체로네가 주당 1.55달러에 15,000주 보통주를 매입하여 회사 지분을 늘렸다고 발표했습니다. 이 거래 이후 체로네의 총 보유 주식은 43,252,143주 보통주로 증가했으며, 이는 회사 발행 주식 자본의 37.02%에 해당합니다. 티지아나는 면역조절 치료제를 개발 중이며, 주요 후보 물질은 완전 인간형 항-CD3 단클론 항체인 비강 투여용 포랄루맙입니다.
Tiziana Life Sciences (NASDAQ : TLSA) a annoncé que le Président exécutif et fondateur Gabriele Cerrone a augmenté sa participation dans la société en achetant 15 000 actions ordinaires au prix de 1,55 $ par action. À la suite de cette transaction, la détention totale de Cerrone s’élève à 43 252 143 actions ordinaires, représentant 37,02 % du capital social émis par la société. Tiziana développe des thérapies d’immunomodulation, avec comme principal candidat le foralumab intranasal, un anticorps monoclonal anti-CD3 entièrement humain.
Tiziana Life Sciences (NASDAQ: TLSA) gab bekannt, dass der Executive Chairman und Gründer Gabriele Cerrone seinen Anteil am Unternehmen durch den Kauf von 15.000 Stammaktien zu je 1,55 $ pro Aktie erhöht hat. Nach dieser Transaktion beläuft sich Cerrones Gesamtbestand auf 43.252.143 Stammaktien, was 37,02 % des ausgegebenen Aktienkapitals des Unternehmens entspricht. Tiziana entwickelt Immunmodulationstherapien, wobei der führende Kandidat das intranasale Foralumab ist, ein vollständig humaner anti-CD3 monoklonaler Antikörper.
- Insider buying demonstrates management's confidence in the company's future
- Executive Chairman increases significant ownership stake to 37.02% of the company
- The purchase price of $1.55 per share sets a perceived value benchmark
- None.
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announces that its Executive Chairman and Founder, Mr. Gabriele Cerrone, has purchased 15,000 common shares at
About Foralumab
Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 10 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).
Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. The non-active SPMS intranasal foralumab Phase 2 trial (NCT06292923) began screening patients in November of 2023. Immunomodulation by intranasal foralumab represents a novel avenue for treatment of neuroinflammatory and neurodegenerative human diseases.[1],[2]
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.
For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
[1] https://www.pnas.org/doi/10.1073/pnas.2220272120
[2] https://www.pnas.org/doi/10.1073/pnas.2309221120
FAQ
How many shares did TLSA Chairman Gabriele Cerrone purchase in May 2025?
What percentage of Tiziana Life Sciences (TLSA) does Chairman Cerrone own after his May 2025 purchase?
What is Tiziana Life Sciences' (TLSA) main development candidate?
What was the share price of TLSA Chairman Cerrone's May 2025 purchase?
